NCT07439744Recruiting
NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status
Effects of 12-week n-3 PUFA Treatment (EPA) on Depressive Symptoms in Overweight/Obese Depressed Subjects With Low n-3 PUFA Status: Relationship With Systemic Inflammation
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 5 Feb 2026
- Start date
- 1 Mar 2025
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- National Science and Technology Council, Taiwan
- Diseases
- Obesity
- NCT number
- NCT07439744
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 1 Mar 2025 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Alcohol or drug abuse/dependence (except for nicotine)
Other illness
- Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)
- Obsessive-compulsive disorder
- Post-traumatic stress disorder
- Serious medical/neurological conditions, especially requiring corticosteroid/non-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement
Other
- Schizophrenia
- Mania
- Active suicidal ideation
Who the study is looking for
- Major depressive disorder.
- Antidepressant drug-free.
Age in the registry: 18 years to 54 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mind-Body Interface Research Center (MBI Lab & Care) Coordinator of this site? Confirm its status | Taichung | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.